Skip to main content
OpenTrials

Clinical trial condition

Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

Explore clinical trials studying Resectable Pancreatic Ductal Adenocarcinoma (PDAC). Study availability and eligibility vary by location and protocol.

2 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Resectable Pancreatic Ductal Adenocarcinoma (PDAC) trial results

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +10 more
Locations
  • Cedars-Sinai Cancer at Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of California, Los Angeles Los Angeles, California, United States
  • Stanford Cancer Institute Palo Alto, California, United States
  • University of California, San Francisco San Francisco, California, United States
View all 43 locations
View Trial Details
Completed

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

NCT03727880

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +7 more
Locations
  • Samuel Oschin Cancer Center at Cedars-Sinai Los Angeles, California, United States
  • Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
  • The University of Texas Health Science Center San Antonio San Antonio, Texas, United States
View Trial Details

Related conditions